Phenanthridin-6-one derivatives as the first class of non-steroidal pharmacological chaperones for Niemann-Pick disease type C1 protein.
暂无分享,去创建一个
Hiromitsu Fukuda | Minoru Ishikawa | Kenji Ohgane | Yuichi Hashimoto | Tomomi Noguchi-Yachide | Kosuke Dodo | Y. Hashimoto | M. Ishikawa | K. Dodo | Kenji Ohgane | Fumika Karaki | Tomomi Noguchi-Yachide | Fumika Karaki | Hiromitsu Fukuda
[1] Lisa N Kinch,et al. Purified NPC1 Protein , 2008, Journal of Biological Chemistry.
[2] Satoshi Ishii,et al. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease , 1995 .
[3] S. Gale,et al. Niemann-Pick Type C1 I1061T Mutant Encodes a Functional Protein That Is Selected for Endoplasmic Reticulum-associated Degradation Due to Protein Misfolding* , 2008, Journal of Biological Chemistry.
[4] Barbara Karten,et al. Mechanisms and consequences of impaired lipid trafficking in Niemann-Pick type C1-deficient mammalian cells. , 2009, Biochimica et biophysica acta.
[5] Kenji Ohgane,et al. Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect. , 2013, Bioorganic & medicinal chemistry.
[6] Joseph L. Goldstein,et al. Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes. , 2010, Cell metabolism.
[7] M. Makishima,et al. LXR ANTAGONISTS WITH A 5-SUBSTITUTED PHENANTHRIDIN-6-ONE SKELETON : SYNTHESIS AND LXR TRANSREPRESSION ACTIVITIES OF CONFORMATIONALLY RESTRICTED CARBA-T0901317 ANALOGS , 2008 .
[8] Paul Helquist,et al. Treatment of Niemann–Pick Type C Disease by Histone Deacetylase Inhibitors , 2013, Neurotherapeutics.
[9] D. Mangelsdorf,et al. An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.
[10] Minoru Ishikawa,et al. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.
[11] D. Mangelsdorf,et al. Role of LXRs in control of lipogenesis. , 2000, Genes & development.
[12] Timothy M Willson,et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. , 2002, Journal of medicinal chemistry.
[13] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[14] F. Sharom,et al. Characterization of Fluorescent Sterol Binding to Purified Human NPC1* , 2009, Journal of Biological Chemistry.
[15] S. Angers,et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.
[16] Kenji Ohgane,et al. Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein. , 2014, Bioorganic & medicinal chemistry letters.
[17] Kenji Ohgane,et al. Discovery of oxysterol-derived pharmacological chaperones for NPC1: implication for the existence of second sterol-binding site. , 2013, Chemistry & biology.
[18] Brian K. Kobilka,et al. Structural Instability of a Constitutively Active G Protein-coupled Receptor , 1997, The Journal of Biological Chemistry.
[19] A. Lieberman,et al. Ryanodine receptor antagonists adapt NPC1 proteostasis to ameliorate lipid storage in Niemann-Pick type C disease fibroblasts. , 2012, Human molecular genetics.
[20] Joseph L Goldstein,et al. Purified NPC1 Protein , 2008, Journal of Biological Chemistry.
[21] D. Clarke,et al. Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators* , 1997, The Journal of Biological Chemistry.
[22] Martin Bard,et al. An “Exacerbate-reverse” Strategy in Yeast Identifies Histone Deacetylase Inhibition as a Correction for Cholesterol and Sphingolipid Transport Defects in Human Niemann-Pick Type C Disease*♦ , 2011, The Journal of Biological Chemistry.
[23] K. Yamakawa,et al. Genotype-phenotype relationship of Niemann-Pick disease type C: a possible correlation between clinical onset and levels of NPC1 protein in isolated skin fibroblasts , 2000, Journal of medical genetics.
[24] P. Gascón,et al. The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann–Pick type C patients carrying missense mutations , 2014, The FEBS journal.
[25] G. Millat,et al. Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. , 1999, American journal of human genetics.
[26] Hiromitsu Fukuda,et al. Structure-activity relationship study of non-steroidal NPC1L1 ligands identified through cell-based assay using pharmacological chaperone effect as a readout. , 2014, Bioorganic & medicinal chemistry.
[27] J. Storch,et al. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. , 2009, Biochimica et biophysica acta.
[28] Joseph L. Goldstein,et al. Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol , 2009, Cell.
[29] M. Makishima,et al. Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton. , 2012, Journal of medicinal chemistry.
[30] Katsumi Higaki,et al. Endoplasmic Reticulum-associated Degradation of Niemann-Pick C1 , 2014, The Journal of Biological Chemistry.